MS500 ASSOCIATION STUDY OF ABCB1 AND 5HT2C GENETIC POLYMORPHISMS AND METABOLIC SYNDROME IN FEMALE PATIENTS WITH SCHIZOPHRENIA

Abstract

Background: Second generation antipsychotic (SGAs) drugs have brought significant progress in treatment of schizophrenia. However, among patients who respond to treatment well, there is a significant number of those who develop metabolic syndrome (about 50%). Interindividual differences in responses to SGAs point out that genetic factor may be relevant. The objective of this study was to determine the association of genetic polymorphism of 5-HT2c and ABCB1 and metabolic abnormalities among female patients with DSM IV schizophrenia spectrum disorders treated with SGAs. Methods: We recruited 121 female schizophrenic patients following DSM-IV criteria, who were acutely psychotic and treated with olanzapine or risperidone for up to 3 months. Metabolic syndrome developement (which included assessment of the increase of fasting glucose levels in blood, fasting total cholesterol, LDL, HDL and triglyceride levels, blood pressure and waist and hip circumferences and body mass index) was assessed. Genomic DNA was isolated from a whole blood sample of patients and exon 21 2677G>T/A and exon 26 3435C>T gene variants of ABCB1 were identified by Real time PCR method in Roche LightCyclerâ. -759C>T of 5-HT2c gene was analysed by PCR-RFLP method. Results: We found a significant association of -759CT 5-HT2c and the increase of waist circumference, fasting glucose and triglycerides in blood after a 3-month period. 2677GT ABCB1 variants were significantly associated with the increase of fasting glucose in SGA-treated patients. Our data indicate a possible influence of -759CT 5-HT2c and ABCB1 2677GT genetic polymorphisms on the development of metabolic abnormalities among female patients treated with SGAs.